Literature DB >> 16696584

Spotlight on quetiapine in acute mania and depression associated with bipolar disorder.

Toni M Dando1, Gillian M Keating.   

Abstract

Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696584     DOI: 10.2165/00023210-200620050-00009

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  9 in total

1.  Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.

Authors:  Eduard Vieta; Jamie Mullen; Martin Brecher; Björn Paulsson; Martin Jones
Journal:  Curr Med Res Opin       Date:  2005-06       Impact factor: 2.580

2.  A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

Authors:  Joseph R Calabrese; Paul E Keck; Wayne Macfadden; Margaret Minkwitz; Terence A Ketter; Richard H Weisler; Andrew J Cutler; Robin McCoy; Ellis Wilson; Jamie Mullen
Journal:  Am J Psychiatry       Date:  2005-07       Impact factor: 18.112

3.  Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.

Authors:  Roger S McIntyre; Martin Brecher; Björn Paulsson; Karin Huizar; Jamie Mullen
Journal:  Eur Neuropsychopharmacol       Date:  2005-04-18       Impact factor: 4.600

4.  A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.

Authors:  Charles L Bowden; Heinz Grunze; Jamie Mullen; Martin Brecher; Björn Paulsson; Martin Jones; Mårten Vågerö; K Svensson
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

5.  Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment.

Authors:  P T Thyrum; Y W Wong; C Yeh
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2000-05       Impact factor: 5.067

6.  Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.

Authors:  Lakshmi N Yatham; Björn Paulsson; Jamie Mullen; And Mårten Vågerö
Journal:  J Clin Psychopharmacol       Date:  2004-12       Impact factor: 3.153

7.  Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders.

Authors:  George E Jaskiw; Per T Thyrum; Matthew A Fuller; Lisa A Arvanitis; Chiao Yeh
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.

Authors:  G Sachs; K N R Chengappa; T Suppes; J A Mullen; M Brecher; N A Devine; D E Sweitzer
Journal:  Bipolar Disord       Date:  2004-06       Impact factor: 6.744

9.  A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.

Authors:  Melissa P Delbello; Michael L Schwiers; H Lee Rosenberg; Stephen M Strakowski
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-10       Impact factor: 8.829

  9 in total
  1 in total

1.  Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex.

Authors:  Satoshi Yamamura; Keiko Ohoyama; Tatsuya Hamaguchi; Kanae Kashimoto; Masanori Nakagawa; Shinichi Kanehara; Dai Suzuki; Takuya Matsumoto; Eishi Motomura; Takashi Shiroyama; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2009-07-03       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.